Navigation Links
Neurological and executive function impairment associated with breast cancer
Date:11/14/2011

CHICAGO Women who survive breast cancer show significant neurological impairment, and outcomes appear to be significantly poorer for those treated with chemotherapy, according to a report in the November issue of the Archives of Neurology, one of the JAMA/Archives journals.

Breast cancer (BC) is one of the most common public health problems, with a worldwide estimated incidence of 39 per 100,000 individuals annually. Although primary BC has not been associated historically with neurological problems, a growing body of evidence suggests that patients are at increased risk for altered brain structure and function, according to background information in the article.

Shelli R. Kesler, Ph.D., and colleagues at Stanford University School of Medicine, Stanford, Calif., conducted an observational study to determine whether profiles of brain activation differ among BC survivors treated with or without chemotherapy, compared with healthy control women. The study included 25 women with BC who received chemotherapy, 19 women with BC who did not receive chemotherapy, and 18 healthy female controls, all matched for age and other demographic variables. The women were asked to perform various tasks, and the researchers used functional MRI to measure activation in several areas of the brain.

"Women with BC demonstrated significantly reduced activation in the left middle dorsolateral prefrontal cortex and premotor cortex compared with healthy controls," the authors report.

"The chemotherapy group also demonstrated significantly reduced left caudal lateral prefrontal cortex activation and increased perseverative errors and reduced processing speed compared with the other two groups," they write.

The study also found that the negative effects of chemotherapy on brain function may be exacerbated by such factors as increased age and lower educational level.

"This study provides further evidence that primary BC may cause measurable brain injury," the authors conclude. "Women treated with chemotherapy may show additional prefrontal deficits and have difficulty compensating for neurobiological changes such that they also show impaired executive function."


'/>"/>

Contact: Michelle Brandt
mbrandt@stanford.edu
650-723-0272
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Neurological disorder impacts brain cells differently
2. Harvard Medical School and EPFL launch program targeting neurological disabilities
3. Researcher tests drugs impact on neurological disease affecting women
4. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
5. Neurological protein may hold the key to new treatments for depression
6. Elseviers BrainNavigator 3.0 reflects the next step in enhancing neurological research
7. NYU researchers identify new neurological deficit behind lazy eye
8. Scientists explain the neurological process for the recognition of letters and numbers
9. Team led by LA BioMed scientist develops novel approach to study neurological disorders
10. University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation
11. University Hospitals Neurological Institute hosts international epilepsy colloquium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... company is unveiling its revolutionary new 2.0 version at the International Roofing Expo ... “put the power of the world's most advanced weather technology in the hands ...
(Date:2/10/2016)... Garland, TX (PRWEB) , ... February 10, 2016 ... ... the commencement of a master charity program created to assist the local community. ... closely with community leaders and nonprofit organizations in the area. Their goal is ...
(Date:2/10/2016)... ... , ... Ongoing news of the ravages of traumatic brain injury (TBI) among ... that takes a closer look at cases of TBI being managed by their members. ... among the aging population, and identifies the challenges associated with their care. , During ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... been awarded the prestigious Distinguished Emerald Club of the World award, as determined ... magazine, one of the most respected trade publications serving private clubs. , “We’d ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Jersey and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the ... Series D investment round on February 5, 2016. The ... Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, and ... SCP Vitalife Partners, Generali Financial Holdings and both the ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
Breaking Medicine Technology: